Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of April 8, 2024
Click Here to Manage Email Alerts
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more.
Read the full coverage here:
PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes
Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases
VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab
VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Early safety, efficacy results positive for Restoret in DME, wet AMD
References:
Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Collapse
Click Here to Manage Email Alerts
